Fulltext

Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure

Taghavi SM 1 , Fatemi SS 2 , Rokni H 3

Affiliations 

  • 1 Seyyed Morteza Taghavi. Mashhad Medical University, Endocrinology, Ahmad Abad, Mashhad, Khorasan 9187883655 Iran (Islamic Republic Of). taghavimr@mums.ac.ir
  • 2 Seyyede Sedighe Fatemi. Mashhad Medical University, Endocrinology, Ahmad Abad, Mashhad, Khorasan 9187883655 Iran (Islamic Republic Of).
  • 3 Hale Rokni. Mashhad Medical University, Endocrinology, Ahmad Abad, Mashhad, Khorasan 9187883655 Iran (Islamic Republic Of).
Med J Malaysia, 2012 Aug;67(4):390-2.
PMID: 23082447

Abstract

Ergot-derived dopamine D2 receptor agonists are the usual treatment of hyperprolactinemia and Parkinson's disease and recently bromocriptine has been approved for the treatment of type 2 diabetes. The aim of this study was the evaluation of short-term effect of cabergoline in poorly controlled diabetic patients with oral agent failure who refused insulin therapy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications